← All indications
Blast Crisis
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.
Drugs by status
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 2 Indications (49)
- Incyte
- AbbVie
- ChemGenex Pharmaceuticals
- Eisai
- Takeda
- Celgene
- Bristol-Myers Squibb
- Amgen
- Merck
- Genzyme
- Pfizer
- Ariad Pharmaceuticals
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- Cornell University
- Harvard University
- University of Washington
- Johns Hopkins University
- Rutgers University
- Stanford University
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Michigan
- University of Nebraska
- University of Toronto
- University of Bologna
- University of Versailles
- Mayo Clinic
- +19 more
Organization Involved with Phase 1 Indications (17)
- Karyopharm Therapeutics Inc
- Synta Pharmaceuticals Corp.
- University of Pittsburgh
- New York University
- Northwestern University
- Ohio State University
- University of Maryland
- University of Rochester
- Virginia Commonwealth University
- University of California, Irvine
- Xencor
- Adastra Pharmaceuticals
- Chiltern International
- The Leukemia and Lymphoma Society
- Alex's Lemonade Stand Foundation
- William Lawrence and Blanche Hughes Foundation
- d3 Medicine
Organization Involved with Other Experimental Indications (2)